Clinical Textbook of Addictive Disorders 3rd ed - R. Frances, S. Miller, A. Mack (Guilford, 2005) WW

182 III. SUBSTANCES OF ABUSESchwartz, R. H., & Miller, N. S. (1997). MDMA (Ecstasy) and the rave: A review. Pediatrics,100, 705–708.Scrima, L., Hartman, P. G., Johnson, F. H., Jr., Thomas, E. E., & Hiller, F. C. (1990).The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: Adouble-blind study. Sleep, 13, 479–490.Shannon, M. (2000). Methylenediocyamphetimine (MDMA, Ecstasy). Ped Emer Care,16, 377–380.Shulgin, A. (1986). The background and chemistry of MDMA. J Psychoactive Drugs, 18,291–304.Shulgin, A. (1990). History of MDMA. In S. J. Peroutka (Ed.), Ecstasy: The clinical,pharmacological and neurotoxicological effects of the drug MDMA (pp. 1–20). Boston:Kluwer Academic.Siegel, R. K. (1984). The natural history of hallucinogens. In B. L. Jacobs (Ed.), Hallucinogens:Neurochemistry, behavioral, and clinical perspectives (pp. 1–17). New York:Raven Press.Solowij, N. (1998). Cannabis and cognitive functioning. Cambridge, UK: Cambridge UniversityPress.Solowij, N., Michie, P. T., & Fox, A. M. (1995). Differential impairments of selectiveattention due to frequency and duration of cannabis use. Biol Psychiatry, 37, 731–739.Sprague, J. E., Everman, S. L., & Nichols, D. E. (1998). An integrated hypothesis forthe serotonergic axonal loss induced by 3,4- methylenedioxymethamphetamine.Neurotoxicology, 19, 427–441.Sugiura, T., & Waku, K. (2002). Cannabinoid receptors and their endogenous ligands. JBiochem, 132, 7–12.Takahara, J., Yunoki, S., Yakushiji, W., Yamauchi, J., Yamane, Y., & Ofuji, T. (1977).Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactinrelease in humans. J Clin Endocrinol Metab, 44, 1014–1018.Tramer, M. R., Carroll, D., Campbell, F. A., Reynolds, D. J. M., Moore, R. A., &McQuay, H. J. (2001). Cannabinoids for control of chemotherapy induced nauseaand vomiting: Quantitative systematic review. Br Med J, 323, 16–32.Tunnicliff, G., & Raess, B. U. (2002). Gamma-hydroxybutyrate (orphan medical). CurrOpin Investig Drugs, 3, 278–283.Turner, J. J., & Parrott, A. C. (2000). “Is MDMA a human neurotoxin?”: Diverse viewsfrom the discussants. Neuropsychobiology, 42(1), 42–48.United Nations. (1997). World drug report. Retrieved February 2, 2004, fromwww.un.org/ga/20special/wdr/e_hilite.htmVerkes, R. J., Gijsman, H. J., Pieters, M. S., Schoemaker, R. C., de Visser, S., Kuijpers,M., et al. (2001). Cognitive performance and serotonergic function in users ofecstasy. Psychopharmacology, 153, 196–202.Vickers, M. D. (1969). Gamma-hydroxybutyric acid. Int Anesth Clin, 71, 75–89.Vinciguerra, V., Moore, T., & Brennan, E. (1988). Inhalation marijuana as anantiemetic for cancer chemotherapy. NY State Med J, 88, 525–527.Walgate, R. (2003, September 16). Retracted Ecstasy paper “An outrageous scandal.”The Scientist. Retrieved February 2, 2004, from www.biomedcentral.com/news/20030916/04Walton, R. (1938). America’s new drug problem. Philadelphia: Lippincott.